ReviewPrednisone in lupus nephritis: How much is enough?
Introduction
Lupus nephritis (LN) is present in 35 to 40% of adults with systemic lupus erythematosus (SLE), being a well recognized factor of morbidity and mortality [1]. Several consensus guidelines focusing on the management of LN have been recently developed [2], [3], [4]. All agree in recommending a 3 to 6-month induction phase, followed by a maintenance phase of variable duration [2], [3], [4], [5]. The induction phase usually includes the combination of glucocorticoids with an immunosuppressive agent [6]. Different clinical trials have addressed the efficacy of immunosuppressive drugs, such as cyclophosphamide, azathioprine and mycophenolate mofetil [7], [8], [9], [10], [11], [12], [13]. Concomitant therapy with glucocorticoids, usually at high doses, is the rule; however the impact of steroids in both response and toxicity has been insufficiently analysed. Glucocorticoid schedules are only partially explained in most studies and dosages are frequently modified during the follow up [14].
Due to the lack of solid evidence supporting the use of high dose glucocorticoids and given our concern for adverse effects, our group has been using reduced doses of prednisone in the treatment of lupus, on the assumption that they can be as effective as and safer than higher doses. Our aim in this study is to address the effectiveness and safety of our therapeutic scheme in patients with LN.
Section snippets
Study design and patients
We designed a comparison study between two groups of patients with LN from the Lupus-Cruces observational cohort: those patients treated with a defined protocol using medium doses of prednisone at induction, the ‘Cruces-protocol cohort’ (CPC), and with at least one year of follow-up, were compared with those from the ‘historic cohort’ (HC), treated with a protocol similar to the National Institute of Health (NIH) scheme. Each of the 15 patients of the CPC was matched with two patients from the
Demographic and SLE-related variables
Forty-five patients were included in the analysis. The demographic and baseline clinical characteristics of the patients are shown in Table 2. At the time of the diagnosis of LN, the GFR, serum albumin levels, C3 values and the proportion of patients with anti-dsDNA antibodies were similar in both cohorts. Hematuria was almost universal. The mean 24 hour proteinuria was significantly higher in the HC. Three of 15 patients (20%) had hypertension in the CPC vs. 12/30 patients (40%) in the HC. The
Discussion
High-dose glucocorticoids, usually 1 mg/kg/d of prednisone for periods not shorter than 2 to 4 weeks with variable tapering schedules, have been the rule to treat severe manifestations of SLE whatever the accompanying immunosuppressive regime [13], [18], [19]. However, the basis for using such doses, the duration of therapy and the tapering schedule are essentially empirical [20], [21].
The anti-inflammatory properties of glucocorticoids mediated by transrepression at the genomic level [22] are
Competing interests
The authors declare that they have no competing interests.
Take-home messages
- •
Although empirical, schemes containing high-dose prednisone are almost universally used for the induction therapy of lupus nephritis.
- •
This study shows that combination therapy using medium-dose prednisone is associated with less glucocorticoid-related toxicity.
- •
Our results also point to a quicker and sustained response in patients treated with medium-dose prednisone regimes.
Acknowledgements
Dr. Álvaro Danza was supported by a grant from the Universidad de la República (Uruguay).
References (47)
- et al.
Treatment of lupus nephritis: a meta-analysis of clinical trials
Am J Kidney Dis
(1997) - et al.
Lupus nephritis: a critical review
Autoimmun Rev
(2012) - et al.
Long-term complications of past glucocorticoid use
Autoimmun Rev
(2013) - et al.
Optimised glucocorticoid therapy: the sharpening of an old spear
Lancet
(2005) - et al.
SLE diagnosis and treatment: when early is early
Autoimmun Rev
(2010) - et al.
Corticosteroid use and its association with microalbuminuria in the adult population
Pulm Pharmacol Ther
(2003) - et al.
Cushing's syndrome, glucocorticoids and the kidney
Gen Comp Endocrinol
(2010) The treatment of SLE: the case for conservative management
Clin Rheum Dis
(1982)- et al.
Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center
Medicine (Baltimore)
(1999) - et al.
American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis
Arthritis Care Res (Hoboken)
(2012)
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
Ann Rheum Dis
Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.)
Nefrologia
Current management of lupus nephritis: popular misconceptions
Lupus
Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
N Engl J Med
Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis
Ann Intern Med
Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide
Arthritis Rheum
EULAR randomized controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophsphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis
Ann Rheum Dis
Sequential therapies for proliferative lupus nephritis
N Engl J Med
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
N Engl J Med
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis
J Am Soc Nephrol
Reporting of corticosteroid use in systemic disease trials: evidence from a systematic review of the potential impact on treatment effect
Arthritis Care Res (Hoboken)
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
Arthritis Rheum
The 1982 revised criteria for the classification of systemic lupus erythematosus
Arthritis Rheum
Cited by (65)
Systemic lupus erythematosus and glucocorticoids: A never-ending story?
2023, Best Practice and Research: Clinical RheumatologyLupus nephritis: new progress in diagnosis and treatment
2022, Journal of AutoimmunityEfficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
2021, The LancetCitation Excerpt :These results are encouraging as the rapid reduction of proteinuria within the first year of treatment is a crucial outcome associated with preservation of kidney function and improvement of long-term outcomes.4–6,8 This study showed that a rapidly tapered low-dose steroid regimen can be effective in the treatment of lupus nephritis, reducing the risk of organ damaging and toxic effects of prolonged corticosteroid use.20,21 The steroid regimen used in both treatment groups of this study resulted in lower steroid exposure while maintaining efficacy; the control group in this study achieved complete renal response rates consistent with historical studies involving higher steroid doses.9,10,13
Balancing risks and benefits in the use of hydroxychloroquine and glucocorticoids in systemic lupus erythematosus
2024, Expert Review of Clinical Immunology